Vitura Health Gelecekteki Büyüme
Future kriter kontrolleri 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Vitura Health.
Anahtar bilgiler
n/a
Kazanç büyüme oranı
n/a
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 54.6% |
Gelir büyüme oranı | n/a |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | None |
Son güncelleme | n/a |
Gelecekteki son büyüme güncellemeleri
Recent updates
There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise
Oct 17Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Oct 13Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture
Sep 07Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings
Aug 12Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Aug 12The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%
Apr 25Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Apr 11Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%
Feb 27Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Feb 25Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)
Dec 13Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet
Nov 21Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?
Nov 01Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Jul 18Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%
Sep 12If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity
Sep 05Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Vitura Health yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.
SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
6/30/2024 | 124 | 4 | 6 | 7 | N/A |
3/31/2024 | 122 | 6 | 8 | 9 | N/A |
12/31/2023 | 120 | 9 | 11 | 11 | N/A |
9/30/2023 | 119 | 12 | 10 | 10 | N/A |
6/30/2023 | 117 | 14 | 9 | 10 | N/A |
3/31/2023 | 107 | 12 | 9 | 10 | N/A |
12/31/2022 | 97 | 10 | 9 | 10 | N/A |
9/30/2022 | 82 | 8 | 11 | 12 | N/A |
6/30/2022 | 67 | 6 | 13 | 14 | N/A |
3/31/2022 | 54 | 5 | 11 | 11 | N/A |
12/31/2021 | 42 | 5 | 9 | 9 | N/A |
9/30/2021 | 32 | 3 | 5 | 5 | N/A |
6/30/2021 | 22 | 1 | 1 | 1 | N/A |
3/31/2021 | 15 | 0 | 0 | 0 | N/A |
12/31/2020 | 7 | -2 | -1 | -1 | N/A |
9/30/2020 | 4 | -3 | -3 | -3 | N/A |
6/30/2020 | 0 | -4 | -5 | -5 | N/A |
3/31/2020 | 0 | -4 | -4 | -4 | N/A |
12/31/2019 | N/A | -4 | -4 | -4 | N/A |
9/30/2019 | N/A | -3 | -3 | -3 | N/A |
6/30/2019 | N/A | -3 | -2 | -2 | N/A |
6/30/2018 | 0 | 0 | 0 | 0 | N/A |
6/30/2017 | 0 | 0 | N/A | 0 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: Insufficient data to determine if VIT's forecast earnings growth is above the savings rate (2.4%).
Kazançlar ve Piyasa: Insufficient data to determine if VIT's earnings are forecast to grow faster than the Australian market
Yüksek Büyüme Kazançları: Insufficient data to determine if VIT's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: Insufficient data to determine if VIT's revenue is forecast to grow faster than the Australian market.
Yüksek Büyüme Geliri: Insufficient data to determine if VIT's revenue is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if VIT's Return on Equity is forecast to be high in 3 years time